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AbstrACt
Introduction Anorexia nervosa (AN) is an eating disorder 
characterised by restriction of energy intake, fears of 
gaining weight and related body image disturbances. 
The oxytocinergic system has been proposed as a 
pathophysiological candidate for AN. Oxytocin is a 
neuropeptide involved in bodily processes (eg, breast 
feeding) and in the onset of social behaviours (eg, 
bonding). Studies investigating the effect of intranasal 
oxytocin (IN-OT) in AN showed that it can improve 
attentional bias for high-calorie food and fat bodies stimuli, 
and related stress. However, less is known about the effect 
of IN-OT on bodily awareness and body image distortions, 
key features of the disorder linked to its development, 
prognosis and maintenance. Here, we aim to investigate 
the effect of IN-OT on the perception of affective, 
C-tactile-optimal touch, known to be impaired in AN and 
on multisensory integration processes underlying a body 
ownership illusion (ie, rubber hand illusion). For exploratory 
purposes, we will also investigate the effect of IN-OT on 
another interoceptive modality, namely cardiac awareness 
and its relationship with affective touch.
Design, methods and analysis Forty women with AN 
and forty matched healthy controls will be recruited and 
tested in two separate sessions; self-administering IN-OT 
(40 IU) or placebo, intranasally, in a pseudo-randomised 
manner. The data from this double-blind, placebo-
controlled, cross-over study will be analysed using linear 
mixed models that allow the use of both fixed (treatment 
levels) and random (subjects) effects in the same analysis. 
To address our main hypotheses, separate analyses will 
be run for the affective touch task, where the primary 
outcome dependent variable will be the pleasantness 
of the touch, and for the rubber hand illusion, where we 
will investigate multisensory integration quantified as 
subjective embodiment towards the rubber hand. In the 
latter, we will manipulate the synchronicity of touch and 
the size of the hand.
Ethics and dissemination Ethics approval has been 
obtained by National Research Ethics Service NRES 
Committee London (Queen’s Square Committee, ref 
number 14/LO/1593). The results will be disseminated 
through conference presentations and publication in peer-
reviewed journals.
IntroDuCtIon  
Anorexia nervosa (AN) is an eating disorder 
characterised by restriction of energy intake, 
fears of gaining weight and related body 
shape and size disturbances.1 AN is associ-
ated with severe morbidity and yields the 
highest mortality rate of any psychiatric 
illness (5%–7%2). The aetiology is not fully 
understood; however, there is significant 
progress in formulating mechanism-based 
rather than diagnosis-based models and the 
appreciation that AN is heterogeneous and 
shares dimensions of psychopathology with 
other psychiatric illnesses.3 4 Nevertheless, 
despite this progress, treatment outcomes 
strengths and limitations of this study
 ► The first experimental study to investigate the effect 
of intranasal oxytocin on the perception and integra-
tion of interoceptive and exteroceptive modalities, 
and their role in body representation, in people with 
anorexia nervosa.
 ► The first study to examine the role of intranasal 
oxytocin on explicit and implicit, experimental mea-
sures of body image and representation in anorexia 
nervosa.
 ► One of the few studies to have sufficient power 
(0.80) to investigate the effect of intranasal oxytocin 
on embodied, behavioural and affective tasks in a 
double blind, placebo-controlled, crossover study in 
a female sample, combining participants with and 
without anorexia nervosa.
 ► A limitation of this study is that it will investigate 
the effect of a single dose of intranasal oxytocin; 
therefore, no conclusions about dose-response or 
longitudinal treatment effects can be drawn.
 ► Future studies could include a group who have re-
covered from anorexia nervosa to provide a better 
understanding of the relationship between oxytocin, 
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to date are modest and randomised control trials have 
higher drop-out rates than other psychiatric conditions.5 
One reason is AN’s ‘ego-syntonic’ nature, with some 
patients experiencing their restrictive eating as adaptive 
given their anxieties about their body image and fears of 
losing control over it.6 Unfortunately, body awareness and 
related body image distortions fall outside the scope of 
current biopsychosocial models of AN3 (but see ref 7 for 
recent conceptualisations). This study will explore for the 
first time the relation between multisensory body aware-
ness, including interoceptive perception and awareness 
(ie, the sense of the physiological condition of the body8), 
and a pathophysiological candidate for AN, namely the 
oxytocinergic system.
Recent studies suggest that oxytocin (OT) may be 
involved in the pathophysiology of AN (see refs 9 10 for 
reviews). OT is a neuropeptide consisting of nine amino 
acids, synthesised in the hypothalamus. OT acts both 
peripherally as a hormone and centrally as a neurotrans-
mitter (see ref 11 for reviews). Patients with AN have 
reduced central12 (see ref 13 for a systematic review 
and meta-analysis) and peripheral level14 of OT at base-
line and in response to stimulation with estrogens.15 In 
underweight patients, low OT levels might enhance the 
retention of cognitive distortions of the negative conse-
quences of food intake, therefore reinforcing these 
patients’ perseverative worrying with weight gain.9 Other 
studies reported low basal serum OT levels in women 
with AN14 and those with a history of AN who are now 
weight-restored and in partial or full recovery.16 17 These 
data seem to suggest that OT level may be low in women 
with AN regardless of their weight and raise the question 
of whether low OT levels may contribute to symptoms. A 
recent study showed that lower OT levels are associated 
with increased severity of social-emotional functioning 
impairment and greater severity of alexithymia in AN.18 
Double-blind, placebo-controlled studies in AN showed 
that the administration of 40IU intranasal oxytocin 
(IN-OT) can improve attentional bias towards food images 
and stress perception19–22 but not emotional recogni-
tion.22 Furthermore, it has been suggested that OT might 
positively support recovery, by reducing the stress associ-
ated with food intake23 (but see ref 24). However, to our 
knowledge, only two recent studies25 26 so far have inves-
tigated the effect of IN-OT on interoceptive accuracy in 
healthy population reporting inconsistent findings (see 
below for details), but no study investigated such effects 
in AN and in relation to body awareness and body image 
distortions. As aforementioned, body awareness and 
body image distortions are important and long-identified 
facets of the disorder, linked to development, prognosis 
and maintenance of AN, as well as its relapse.27–29 Never-
theless, these have not received sufficient neuroscientific 
attention as other facets of the disorders such as anxiety, 
cognitive control, or appetitive motivation.30 31
Body awareness and body image distortions can be 
investigated using bodily illusions such as the rubber 
hand illusion (RHI32). The RHI involves conflicts between 
internally felt sensations (eg, proprioception) and exter-
nally seen sensations (eg, touch on the other body). 
Recent studies have investigated multisensory integration 
across interoceptive (ie, cardiac awareness) and extero-
ceptive modalities in the RHI. Specifically, interoception 
accuracy, in the sense of how good or bad participants 
perform in a heartbeat counting task33 seems to predict 
the susceptibility to the RHI, considered as a measure 
of malleability of the sense of body ownership34–36 (but 
see ref 37).
Computational approaches to multisensory integra-
tion38 illusions such as the RHI39 have shown that such 
cross-modal conflicts are resolved in a Bayes-optimal 
manner, by differential weighting of the various sensory 
signals.40 41 Specifically, Zeller and colleagues showed that 
in order to resolve the uncertainty between the conflicting 
visual, proprioceptive and tactile information in the RHI, 
the brain downregulates the precision (the inverse of 
variance in their model42;) of ascending somatosensory 
prediction errors so that they will have less influence on 
top-down, predicted sensory signals about the body.41 43 
In support of this idea, Zeller and colleagues found that 
touch-evoked electroencephalogrophy potentials derived 
by brush-strokes during the RHI are selectively attenuated 
by reducing their precision.43 These results are consistent 
with the idea that in the RHI the precision of somato-
sensory signals (vs precision of visual signals) needs to 
be attenuated in order to resolve conflicting perceptual 
hypotheses about the most likely cause of sensations.41 43
People with AN, as well as sub-clinical eating disorders, 
are particularly susceptible to the visual manipulations of 
multisensory integration paradigms (ie, ‘visual capture’ 
effect), in the sense that they show increased feelings of 
ownership of a fake body part, irrespective of synchro-
nicity between the seen and felt touch.44–46 One possible 
explanation could lie on the fact that they have low 
precision or even deficits in internal, somatosensory and 
interoceptive signals from the body, and thus an over-reli-
ance on visual bodily signals from the outside. Indeed, our 
group and others have already provided some evidence 
for tactile and interoceptive deficits in this population, 
such as perception of taste, pain, cardiac awareness and 
more recently ‘affective touch’.47–52 Most importantly 
for this study, a newly discovered class of C tactile (CT) 
afferents in the human skin that respond preferentially 
to low pressure and slow-velocity dynamic touch are asso-
ciated with the perception of tactile pleasantness,53 and 
positive emotions.54 Accordingly, this modality has been 
redefined as an interoceptive modality, providing infor-
mation about the internal, physiological state of the body 
and clearly separated from other discriminatory, extero-
ceptive sensations8 (see refs 55 56 for reviews). Functional 
imaging studies in humans suggest the posterior insular 
cortex as a primary cortical target for CT-optimal touch 
(see refs 57 58 for a meta-analysis), an area containing a 
primary representation of the physical condition of the 
body and declared as interoceptive cortex.8 59 Thus, CT 








pen: first published as 10.1136/bmjopen-2018-024913 on 15 March 2019. Downloaded from 
3Crucianelli L, et al. BMJ Open 2019;9:e024913. doi:10.1136/bmjopen-2018-024913
Open access
compared with exteroceptive modalities, not least consid-
ering the slow, affective nature of the percept.59 Several 
researchers continue to use the term interoception in 
its classic meaning; however, here we embrace this new 
reclassification of interoception, which includes both 
internally and externally originated bodily signals,56 and 
we think offers an important view on homeostatic and 
affective regulation.8 37 60
Importantly, affective touch has been found to 
play a particularly important role on feelings of body 
ownership in healthy subjects. Specifically, several 
independent studies using the RHI paradigm have 
now shown that this modality enhances the subjective 
feelings and in some studies also objective measures 
of body ownership towards the rubber hand during 
optimal (synchronous) conditions for multisensory 
integration.37 61–63 However, people with AN show 
reduced subjective pleasantness and abnormal brain 
processing in response to CT-optimal touch in compar-
ison to healthy controls,52 64 and no study has assessed 
whether such tactile anhedonia may relate to how 
individuals with AN respond to multisensory integra-
tion paradigms such as the RHI. As aforementioned, 
their tendency to report feelings of body ownership 
for a rubber hand even during suboptimal multisen-
sory integration conditions may relate to the fact that 
somatosensory and interoceptive signals from the 
body are not as strong in this population. The present 
study will be addressing this hypothesis, as well as the 
possibility that IN-OT can enhance feelings of tactile 
pleasure and hence body ownership during optimal 
multisensory integration conditions (ie, synchronous 
touch during the RHI).
Interestingly, interoceptive abnormalities have been 
associated with altered activity in the insular cortex 
(eg, refs 51 65) This area and particularly the right ante-
rior insula was recently linked also to feelings of body 
satisfaction during a body representation task.66 Yet, the 
influence of interoception on body representation in AN, 
and the potential effect of IN-OT on this relationship, 
remain surprisingly unexplored and will be investigated 
in this study as specified below.
Primary aims and hypotheses
This study follows a double-blinded, placebo-con-
trolled, crossover design, with treatment (oxytocin vs 
placebo) as the within-subjects factor (40 IU; two sepa-
rate sessions; randomised allocation AB/BA67). The 
main aims of the study will be to investigate the effect 
of a single dose of IN-OT versus placebo on (1) the 
perceived pleasantness of affective, CT-optimal touch 
and emotionally neutral, non-CT optimal touch and 
(2) the multisensory integration processes underlying 
the classic RHI, as well as (3) an enhanced version in 
which we manipulated the size of the rubber hand, 
in women with AN and healthy controls. Our related 
predictions are outlined below.
First, we hypothesise that IN-OT would enhance the 
perceived pleasantness of touch (both CT-optimal and 
non-CT optimal touch) to a greater extent in people 
with AN compared with healthy controls, that is oxytocin 
will improve the tactile anhedonia which characterises 
AN (ie, main effect of compound; main effect of group 
and significant interaction compound X group, irrespec-
tive of velocity). We expect to see a greater difference in 
pleasantness ratings between groups under the placebo 
condition; in contrast, we anticipate that we will observe a 
smaller difference in pleasantness ratings between groups 
following administration of IN-OT.
A recent behavioural study did not find any effect of 
IN-OT on the hedonic experience of affective touch.68 
However, it should be pointed out that the study did not 
control for contextual effects that could have played a 
role in the experimental setting, such as the gender of the 
person delivering the touch. Furthermore, the sample 
comprised both men and women, with female partici-
pants recruited in different phases of their menstrual 
cycle, and without considering the use of contraceptive 
(see ref 69 for evidence that plasma oxytocin varies across 
the menstrual phase and effect of contraceptive pill on 
hormonal levels). Also, the experimenter delivered the 
touch with his/her hand covered with a silk glove, rather 
than by means of the traditional brush used in studies 
investigating the perception of CT optimal touch53 70 and 
at a CT optimal velocity only. These aspects of the exper-
imental design might have played a role in the perceived 
pleasantness of the touch, and they do not allow firm 
conclusions to be made regarding the specific involve-
ment of the CT afferents system, since a non-CT optimal 
control condition was not included. Therefore, the 
potential effect of IN-OT on tactile pleasantness remains 
an open question, and it should be compared with the 
potential modulation of emotionally neutral touch using 
standard procedures while controlling for velocity of 
touch, gender of the toucher and testing time within the 
menstrual cycle.
Second, we anticipate that IN-OT will lead to stronger 
feelings of subjective embodiment during a RHI para-
digm compared with placebo, and the effect will be 
modulated by synchronicity of touch during the illu-
sion, in the sense that IN-OT would have a larger effect 
following synchronous touch compared with asynchro-
nous touch (ie, main effect of synchronicity, significant 
interaction synchronicity X compound, irrespective of 
group). We expect a main effect of group in the subjec-
tive embodiment, in the sense that we expect the AN 
group to have a stronger experience of the RHI regard-
less of synchronicity of visuotactile simulation (as 
in ref 71). Finally, we predict that IN-OT will enhance 
the multisensory integration process also during the 
RHI with a larger hand. We will observe a main effect of 
group, in the sense that only people with AN will have 
a higher susceptibility to the illusion when they will see 
a larger hand compared with a regular hand, given the 
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We also expect a significant interaction between group 
and compound, with IN-OT increasing this effect in 
people with AN only.
Any significant interaction relative to our main hypoth-
eses will be followed up by appropriate post hoc analyses 
(ie, t-test corrected for multiple comparisons).
secondary exploratory aims and hypotheses
Given that no previous studies on AN or IN-OT have 
assessed some of the cognitive and affective domains of 
interest, and the available time window of IN-OT effects, 
this study also explores a number of secondary hypoth-
eses. These will be accordingly analysed with exploratory 
statistical analyses, the results of which will need to be 
further examined in future confirmatory studies. Specif-
ically, a secondary aim of this study is to explore whether 
any of the hypothesised effects on affective touch in the 
AN group (see above) are specific to this modality or they 
can be generalised to other interoceptive modalities such 
as cardiac awareness. We hypothesise that people with 
AN will show a reduced interoceptive accuracy compared 
with healthy controls. Since interoceptive accuracy can be 
considered as a trait measurement stable in time72 and 
in light of recent studies showing inconsistent effects 
of IN-OT on this modality,25 26 no main effect of IN-OT 
versus placebo on cardiac awareness per se is expected. 
However, we expect to observe differences in the effect 
of IN-OT on interoceptive accuracy between groups (ie, 
a compound by group interaction). Specifically, since 
IN-OT seems to improve attentional bias in AN, we expect 
IN-OT to have a larger effect in improving cardiac aware-
ness in AN compared with healthy controls. Additionally, 
we aim to investigate the relationship between intero-
ceptive accuracy and affective touch (as in ref 37) and 
multisensory integration as measured by means of the 
RHI. We are planning to do so by means of correlational 
analysis and by analysing the effect of velocity of touch 
(CT optimal vs non-CT optimal) on the embodiment of 
the rubber hand.
The same hypotheses described above for the subjective 
embodiment in the RHI will also be investigated in explor-
atory analyses with the perceived location of the partici-
pant’s hand (ie, proprioceptive drift) as a behavioural 
outcome measure of the illusion. Additionally, in the 
subjective measure of the RHI, we will analyse the total 
embodiment score, as well as considering interindividual 
and intraindividual analysis of variance for each of the 12 
items of the embodiment questionnaire separately.
Another secondary aim of this study is also to explore 
whether the effect of IN-OT would be modulated by 
individual differences, such as eating disorders symp-
tomatology, measured by means of the Eating Disorders 
Examination Questionnaire (EDE-Q73). Recent studies 
suggest that (non-clinical) EDE-Q scores might relate to 
body satisfaction following manipulation of illusory body 
size,46 suggesting that this measure can capture sensitivity 
to different body size in healthy population.
MEthoDs AnD MEAsurEs
Participants and recruitment
Inclusion and exclusion criteria
Forty healthy women will be recruited through the 
University College London subject pool system; 40 
women with AN will be recruited at the National Health 
Service North East London Foundation Trust (NELFT) 
and Central and North West London Foundation Trust 
(NoCLOR). All patients will meet the Diagnostic and 
Statistical Manual of Mental Disorders, fourth Edition (1) 
criteria for AN restrictive subtype, as assessed using the 
Structured Clinical Interview for DSM-IV Axis I Disorders. 
Healthy participants will be recruited in the follicular 
phase of their menstrual cycle (between the 5th and 14th 
day) to control for hormonal levels.69 All participants 
will be heterosexual and not taking the contraceptive 
pills.69 Exclusion criteria for both groups include being 
pregnant or breast feeding,74 being below 16 or above 40 
years of age, any visible scar, tattoo or skin condition (eg, 
psoriasis) on the left arm, use of any drugs within the last 
6 months, and consumption of more than five cigarettes 
per day. Exclusion criteria for the healthy controls group 
include a history of any medical, neurological or psychi-
atric illness and body mass index (BMI) out of the range 
18.5–24.9. AN patients will be of restrictive-type only.
Participants will be asked to refrain from consuming 
any alcohol the day before testing and any alcohol or 
coffee on the day of testing. All participants will provide 
informed consent to take part and will receive a compen-
sation of £40 for travelling expenses and time. The study 
will be carried out in accordance with the provisions of 
the Declaration of Helsinki of 1975, as revised in 2008.
Patients’ involvement
Patients were not involved in the development of the 
research question and design of the study. However, clin-
ical psychologists, dieticians, psychiatrists and psychother-
apists working in the eating disorders units associated to 
the project are involved in the screening of patients in 
order to control for eligibility and asses burden of the 
research study in the ongoing treatment. The Informa-
tion Sheet approved by the National Research Ethics 
Service committee specifies the voluntary basis of the 
patients’ participation, their right to withdraw without 
explanation or consequences and their right for a cool-
ing-off period of 7 days. No participant will be recruited 
without written, inform consent. Patients who complete 
the study will be notified with an email about the results 
of the study. Furthermore, findings will be disseminate at 
research days taking place in eating disorders units and in 
public engagements events involving clinicians, patients 
and carers.
Randomisation, blinding and storage
We will use a cross-over design, where each participant 
will receive both IN-OT and placebo. However, the 
order in which participants receive oxytocin/placebo 
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to a treatment order (IN-OT—placebo or the reverse) 
following the stratified method of minimisation, which 
takes into account the age of all the participants, and the 
BMI for the healthy controls group and the years of illness 
for the AN group. This pseudo- randomised procedure 
will be used so as to ensure in each group (AN, healthy 
controls) an equal number of people have received the 
same treatment order (eg, 10 participants will be assigned 
to oxytocin-placebo and 10 participants to the reverse 
order).
Active and placebo sprays will not be identifiable by the 
research team (they will be contained in identical bottles 
marked as spray A and B), ensuring that both researchers 
and participants are blind regarding treatment. The 
blinding letter is in possession of an institutional admin-
istrator not otherwise involved in the study and the 
researchers will be unblinded at the end of the study and 
on completion of data analysis. Both active sprays and 
placebos are safely stored under controlled conditions 
at the laboratories in the Department of Clinical, Educa-
tional and Health Psychology University College London. 
They are stored in a lockable, refrigerator with tempera-
ture monitoring and power failure support features 
between 2°C and 8°C as required by the manufacturer. 
The lab is always locked and access is strictly controlled 
and limited to authorised personnel.
oxytocin and placebo intranasal spray administration
In the present study, participants will receive 40 IU of 
oxytocin (Syntocinon-Spray, Novartis, Basel, Switzerland) 
and placebo (containing the same ingredients as Synto-
cinon except without the active ingredient oxytocin, 
Victoria Apotheke Zuerich, Switzerland) by means of a 
nasal spray. Two practice bottles containing water will be 
used for the participants to familiarise themselves with 
the procedure; one for the experimenter to demonstrate 
and one for the participant to practice. Participants will 
self-administer a puff containing 4IU every 30 s alternating 
between nostrils (five for each nostril) for a total of 10 
puffs. Half of the sample will start the administration on 
the right nostril, and half on the left nostril. The self-ad-
ministration procedure will take about 9 min, including 
3 min of rest at the end.67
study design
The study employs a double-blind, placebo-controlled, 
cross-over design, with compound (oxytocin vs placebo) 
as the within-subjects factor. Each subject (AN or healthy 
control) will participate in two identical sessions, the first 
one lasting approximately 2 hours and the second lasting 
1.5 hours, and scheduled between 1 to 3 days apart; this 
is to ensure that participants are tested in the same phase 
of the menstrual cycle, to ensure consistency of hormonal 
levels.69 Testing sessions will take place between 09:00 and 
12:00 hours, and the time of the day will be kept consis-
tent within participants. In one session, participants will 
be asked to self-administer 40 IU of oxytocin and in the 
other session placebo (see the Session procedure section 
for details and figure 1) in a counter-balanced and 
double-blinded manner. Participants will be pseudoran-
domly allocated to the nasal spray sequence (AB/BA); so 
that half of the participants receive placebo on the first 
visit and IN-OT on the second visit, whereas the order is 
reversed for the other participants.
Measures
Demographic and psychological characteristics
Demographic and psychological characteristics will be 
collected at the beginning of the first testing session. 
Demographics include age, BMI, medication use, medical 
history and relationship status. Participants will complete 
(1) the Depression Anxiety Stress Scales (DASS),75 a 
42-item self-report instrument designed to measure the 
three related negative emotional states of depression, 
anxiety and stress; (2) the Self-Objectification Question-
naire,76 to assess the extent to which participants perceive 
themselves from an external/objectified point of view; 
(3) the Body Awareness Questionnaire,77 an 18-item scale 
designed to assess self-reported attentiveness to body 
processes, such as sensitivity to body cycles and rhythms, 
ability to detect small changes in normal functioning, and 
ability to anticipate bodily reactions; (4) the Autism Spec-
trum Quotient (AQ-10),78 to measure the degree to which 
an individual possesses symptoms typical of the autistic 
spectrum autistic traits (see ref 79 for recent neurobio-
logical evidence supporting the behavioural link between 
AN and autistic traits); (5) the Toronto Alexithymia 
Scale (TAS-20),80 to assess difficulties in identifying and 
describing feelings and (6) EDE-Q,81 to assess disordered 
eating behaviours and attitudes over the past 28 days; the 
questionnaire consists of 36 items on a 7-point forced 
choice rating scale, and it measures weight, shape, eating 
concerns and dietary restrain.
Affective touch
Procedure
For the affective touch procedure, two rectangles will be 
drawn on the hairy skin of the participants left forearm, 
each measuring 4 cm x 9 cm (as in ref 61). Participants 
will place their left arm on the table with palm facing 
down and they will be asked to wear a blindfold to avoid 
visual feedback of the tactile stimuli. Tactile stimulation 
(ie, stroking) will be administered for three seconds using 
a soft cosmetic make-up brush (Natural hair Blush Brush, 
N◦7, The Boots Company) at two different velocities: one 
CT-optimal (3 cm/s: one stroke in 3 s) and one not CT-op-
timal (18 cm/s: six strokes in 3 s). In the present study, a 
total of 16 tactile stimuli will be delivered, eight at slow 
velocity (3 cm/s) and eight at fast velocity (18 cm/s). The 
order of velocity will be randomised and tactile stimula-
tion alternated between the rectangles drawn on the skin, 
to minimise habituation.
Outcome measure
After each brush stroke participants will verbally rate the 
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pleasant), to 100 (extremely pleasant). A copy of the scale 
will be placed on the table for reference. The affective 
touch task will be performed twice at each testing session: 
before and after nasal spray administration.
body ownership: classic, affective and hand size rhI
Procedure
The RHI will be conducted to investigate the effect of 
IN-OT versus placebo on: (1) the classic RHI manipula-
tion, which involves comparing synchronous and asyn-
chronous visuotactile stimulation; (2) the affective RHI, 
which investigates the effect of velocity of touch on the 
occurrence of the illusion (slow vs fast touch); (3) the 
hand size RHI, which explores the effect of hand size on 
the occurrence of the illusion (regular vs larger hand). 
The RHI will be performed following the procedure fully 
described in.37 61 Briefly, in each condition, the experi-
menter will place the participant’s left hand (palm facing 
down; fingers pointing forwards) at a fixed point inside 
a wooden box. Subsequently, the rubber arm will be 
positioned in the right half of the box, in front of the 
participant’s body midline and in the same direction as 
the participant’s actual left arm. The distance between 
the participants’ left arm and the visible arm (on the 
sagittal plane) will be approximately 25 cm. In this study, 
the experimenter then will sit opposite the participant 
and will stroke the previously identified stroking areas82 
for 1 min using a speed of 3 cm/s (slow/pleasant) or 
18 cm/s (fast/neutral). In the synchronous conditions, 
the participant’s left forearm and the rubber forearm 
will be stroked such that visual and tactile feedback will 
be congruent, whereas in the asynchronous conditions, 
visual and tactile stimulation will be temporally incon-
gruent. The asynchronous condition will be run only at 
slow velocity to control for the occurrence of the illusion, 
while the synchronous condition will be repeated three 
times; one at slow velocity, one at fast velocity to control 
for the effect of velocity on the embodiment process and 
one in which participants will be asked to look at a larger 
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hand (in size). The latter condition has been included 
in order to control for the effect of size of the hand on 
the occurrence of the illusion and the effect of IN-OT on 
body size representation. The order of the four conditions 
(slow/synchronous, slow/asynchronous, fast/synchro-
nous, larger hand/synchronous) will be randomised 
between participants, but it will be kept constant within 
participants. Prior to commencing the next condition, 
they will be given a 60 s rest period, during which they will 
be instructed to freely move their left hand.
Illusion measures
A pre-stroking estimate of finger position will then be 
obtained (for the measurement of proprioceptive drift) 
using a tailor’s tape-measure placed on top of the box lid. 
The experimenter will move her finger along the top of 
the box lid on the sagittal plane and participants will be 
asked to say ‘stop’ when the experimenter’s finger is in the 
position where they feel that their own left index finger is 
inside the box. The experimenter then will measure and 
record the difference between the actual and perceived 
position of the participant’s left index finger. After the 
stimulation period, the felt and actual location of the 
participant’s left index finger will be again measured 
following the pre-induction procedure. The difference 
between pre and post-stroking finger position will give a 
measure of the proprioceptive drift.
An embodiment questionnaire83 is used to capture the 
subjective experience of the illusion (12 statements rated 
on a 7-point Likert-type scale; −3, strongly disagree; +3, 
strongly agree). In each condition, the questionnaire is 
administered prestroking (ie, embodiment due to the 
visual capture effect) and poststroking, and we will calcu-
late their difference to obtain a measure of subjective 
embodiment due to visuotactile integration.37 61 This ques-
tionnaire consists of three sub-components: felt ownership, 
that is related to the feeling that the rubber hand is part 
of one’s body; felt location of own hand, that is related to 
the feeling that the rubber hand and one’s own hand are 
in the same place; affect, that includes items related to the 
experience being interesting. We will examine this differ-
ence between pre- and post-stroking (change in embodi-
ment) for each of the statements separately, as well as for 
an overall ‘embodiment of rubber hand’83 score, that will 
be obtained by averaging the scores of the two subcompo-
nents specifically related to embodiment, namely owner-
ship and felt location that did not relate to affect. The 
affect sub-component will also include a measurement of 
the perceived pleasantness of the tactile stimulation using 
a visual analogue scale ranging from 0 to 100 (as in the 
affective touch procedure, see above).
heartbeat baseline and interoceptive accuracy
The participant’s actual heartbeat will be recorded using a 
Biopac MP150 Heart Rate oximeter, and data will be anal-
ysed using AcqKnowledge software V.3.9.2. In the present 
study, a heartbeat baseline of 5 min will be recorded three 
times throughout the experiment; immediately after 
the end of the administration nasal spray (non-active 
post-OT administration, HB1pre), at the beginning of the 
nasal spray active window (active post-OT administration, 
HB2during) and at the end of the experiment (non-active 
post-OT administration, HB3post).
Interoceptive accuracy will be assessed by means of the 
well-established heartbeat detection task,33 where partic-
ipants are asked to count their own heartbeat without 
feeling their chest or taking their pulse. The counting 
procedure will be repeated three different lengths time 
intervals (25, 45 and 65 s) presented in a randomised 
order and separated by a resting time of 30 s. Participants 
will not receive any feedback regarding their perfor-
mance and the interval length. The estimated and actual 
number of heartbeats per time intervals will then be 





recorded heartbeats)   
The interoceptive accuracy scores obtained following 
this transformation can vary between 0 and 1, with higher 
scores indicating a better estimation of the heartbeats 
(ie, smaller differences between estimated and actual 
heartbeats).
session procedure
The experiment is run by two female experimenters. 
After signing the consent form and in the first session 
only, participants are asked to provide a urine sample and 
a pregnancy test (Pregnancy test device, SureScreen Diag-
nostics) is carried out by one experimenter to exclude 
the possibility of any ongoing, unknown pregnancy. This 
is done for safety reasons given the role of oxytocin on 
labour. After confirmation of the negative result of the 
pregnancy test the experimental procedure starts. Partic-
ipants are familiarised with the pleasantness ratings scale 
and with the experimental procedure (above). They are 
asked to place their left arm resting on the table, palm 
down and the two rectangular areas on the forearm are 
marked. Participants then wear the blindfold and are 
asked to rate the pleasantness of the touch.
Subsequently, participants self-administer, under both 
experimenters’ supervision, either IN-OT or the placebo. 
The order of the treatment is counterbalanced across 
participants, and both experimenters and participants 
are blind to the treatment order. Experimental instruc-
tion about the aim of the nasal administration, the posi-
tion of the head and of the nasal spray inside the nasal 
cavity, and breathing technique are given to the partici-
pants. Participants are familiarised to the administration 
procedure by means of a practice nasal spray as described 
above. Before the beginning of the self-administration 
procedure, all the participants are asked to blow their 
nose. Thirty-seconds breaks are given between puffs and 
participants are specifically instructed to not blow their 
nose during the administration procedure.
At the end of the last puff, participants are given 3 min 
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that, the first heartbeat baseline reading is recorded for 
5 min (HB1pre). During the 25 min time post-spray admin-
istration (see refs 67 74 for optimal temporal window) no 
social contact between the participant and the exper-
imenters takes place beyond necessary experimental 
instructions. Participants are asked to refrain from 
checking their phones or doing any personal reading. 
During the waiting time, participants are offered the 
opportunity to complete a Sudoku. At the beginning of 
the active oxytocin window (25 min after the end of the 
administration procedure), the second heartbeat base-
line is recorded for 5 min (HB2during).
Participants then complete the heartbeat detection task 
for the assessment of interoceptive accuracy (see above). 
Following this, the affective touch task and the RHI tasks 
are completed in a counterbalanced order (half of the 
sample follows the post administration order of affective 
touch task-RHI and half of the sample follows the post 
administration order of RHI-affective touch task). After 
completion of the full experimental procedure (that will 
take approximately 45 min), the heartbeat baseline is 
recorded for the last time (HB3post). At the end of each 
testing session, participants are asked to guess whether 
they received IN-OT or placebo to control for any poten-
tial effect of expectations on the observed effects. Our 
experience to date with hundreds of volunteers84 has 
shown that if proper placebo (ie, a nasal spray identical in 
all excipients to Syntocinon except for oxytocin) is used, 
participants cannot distinguish between oxytocin and 
placebo. Participants are fully debriefed and reimbursed 
£40 for their time at the end of the second study visit.
Monitoring adverse events
In the unlikely event that a participant shows side or 
adverse effects to IN-OT, the participant will be withdrawn 
from the study and a new participant will be recruited. 
The study principal investigator will be contacted imme-
diately, she will be un-blinded regarding the nature of the 
compound the participant received in the specific visit 
(IN-OT or placebo) and she will check and monitor the 
participant until they are sure that they are safe to leave 
the premises. After testing, the participant will be advised 
that they will receive a telephone call the next day. The 
principal investigator will telephone the participant to 
check that all is well and report any side or adverse effects 
to the Research Steering Committee following the appro-
priate procedures at the end of the study.
Data analysis
Sample size calculation
We performed a priori sample size calculation (using 
G*Power 3 software85), based on four previous studies 
which investigated the main effect of IN-OT versus 
placebo on behavioural tasks in AN. Specifically, Kim and 
colleagues (2014) investigate the effect of IN-OT versus 
placebo on attention to emotional social stimuli. They 
tested 31 AN patients and 33 healthy controls; following 
a repeated measures procedures they obtained an effect 
size of 0.13. In another study, Kim et al21 investigated 
the impact of oxytocin on food intake and emotion 
recognition. They tested 35 patients with AN and 33 
healthy controls (as well as 34 patients with bulimia 
nervosa). They showed a significant effect on emotion 
recognition, obtaining an effect size of 0.16. Leppanen 
et al22 investigated the effect of IN-OT on the interpretation 
and expression of emotions in AN. Thirty patients with AN 
and 29 healthy controls completed the study, which showed 
no significant differences between IN-OT and placebo, 
with an effect size of 0.17. In another study, Leppanen 
et al22 investigated the effect of IN-OT on attentional bias 
towards food. The sample consisted of 30 patients with 
AN and 29 healthy controls. The repeated measures anal-
ysis showed a significant main effect of IN-OT in reducing 
attentional avoidance to food items, with an effect size 
of 0.19. So on the basis of the studies that have looked 
at the effect of IN-OT on behavioural measures in AN 
we can expect an effect size of between 0.13 and 0.19. 
Here, we run a power calculation on our main, primary 
analyses by looking at the effect of IN-OT versus placebo 
in the two groups on three behavioural measures; affec-
tive touch, embodiment in the classic RHI and embodi-
ment in the enhanced RHI with a larger hand. We took 
also into account the main three interactions of interest 
(group X compound X manipulation of interest); there-
fore, we corrected for multiple comparisons obtaining an 
α of 0.017. We run a power calculation and we observed 
that when α=0.017, considering the standard deviation of 
1, a sample of 30 participants per group will be sufficient 
to obtain a power of 0.80. A drop-out rate (ie, partici-
pants completing only one session) of 30% is assumed for 
sample size calculation to coincide with similar drop-outs 
rates of previous studies86; therefore, we aim to recruit 40 
healthy controls and 40 AN patients.
Statistical analysis plan
Preliminary analyses
Participants who did not follow experimental instruc-
tions, or drop-out after one session will not be considered 
in the data analyses and data will be disposed immedi-
ately. Outliers (above or below 3 SD from the mean in 
each group) will be considered and removed in each 
condition (oxytocin vs placebo) and task separately (ie, 
affective touch; interoceptive accuracy; RHI). We will 
then check the data distribution by means of visual explo-
ration (by looking at Q-Q-Plots) and Shapiro-Wilk tests. 
In the case of a non-normal distribution, appropriate 
log, square root and reciprocal transformations will be 
applied to attempt to correct for the normality violations. 
If following the transformations the data are not normally 
distributed, appropriate non-parametric tests will be used 
to analyse the data (see below).
Preliminary correlation analyses will be conducted to 
investigate the relationships between the psychometric 
measures, namely EDE-Q; DASS; AQ-10; TAS-20 and 
the outcome measures of RHI (embodiment question-
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and interoceptive accuracy. These preliminary analyses 
will inform the inclusion/exclusion of these psycho-
metric measures as co-variates in subsequent analyses. 
In case of a significant correlation between the psycho-
metric measures and the outcome measures, these will be 
included in the analyses as covariates. We will also explore 
the reciprocal relationships between the various psycho-
metric measures to check for multicollinearity and hence 
reduce any such variables.
Main analyses
The data will be analysed using linear mixed models 
(LMM) that allow the use of both fixed and random 
effects in the same analysis. Fixed effects have levels that 
are of primary interest and would be used again if the 
experiment were repeated. Random effects have levels 
that are not of primary interest, but rather are thought 
of as a random selection from a much larger set of levels. 
For example, subject effects are usually treated as random 
effects, while treatment levels are almost always fixed 
effects. An advantage offered by mixed-effects models is 
that hypotheses about the structure of the variance-cova-
riance matrix can be tested by means of maximum likeli-
hood methods that are now in common use in many areas 
of science, medicine and psychophysiology.87 88
Here, separate LMM analyses will be run to test the 
main hypotheses related to (1) pleasantness of touch in 
the affective touch task and measures of embodiment 
following, (2) a classic RHI paradigm (testing body 
ownership) and (3) the enhanced RHI with manipulation 
of the hand size (testing body image). In these analyses, 
order of nasal spray administration (oxytocin-placebo or 
placebo-oxytocin) will be included as a covariate.
Specifically, the perceived pleasantness of touch will be 
analysed by means of a 2×2×2 LMM analysis, where the 
primary outcome dependent variable will be the pleasant-
ness of the touch; velocity of touch, group and compound 
will be the three variables of interest (independent vari-
ables). The preadministration baselines measurements of 
pleasantness from both the experimental sessions will be 
entered as covariates in the LMM analysis.
As specified in our main hypotheses, the data relative to 
the subjective embodiment in the RHI will be analysed by 
means of two separate 2 (compound) x 2 (synchronicity) 
x 2 (group) LMM analyses. One analysis will be run to test 
the effect of synchronicity only on the subjective occur-
rence of the illusion (ie, classic RHI, comparison between 
synchronous and asynchronous touch condition) and the 
interaction between synchronicity, group and nasal spray. 
The second analysis will be run to test the effect of hand 
size in synchronous conditions only on the subjective 
occurrence of the illusion (ie, hand size RHI, comparison 
between normal and larger hand in synchronous condi-
tion only) and the interaction between hand size group 
and nasal spray.
Any significant interactions from the above analyses 
will be followed up by appropriate post hoc analyses, 
correcting for multiple comparisons.
Secondary analyses
As a secondary analysis, we will explore the effect of IN-OT 
on interoceptive accuracy, in the sense of cardiac aware-
ness. The interoceptive (cardiac awareness) scores are 
obtained before and after the nasal spray administration 
and, therefore a LMM analysis will be run with interocep-
tive accuracy postnasal spray administration as the depen-
dent variable, and interoceptive accuracy pre-nasal spray 
as covariate.
Previous research suggests that oxytocin might increase 
heart rate variability89 and therefore the three measure-
ments taken at different stages of the testing procedure 
allow a critical observation of any change in resting heart-
beat activity during the entire study. As mentioned above, 
outliers (above or below 3 SD from the mean in each 
group) will be considered and removed in each condi-
tion (oxytocin vs placebo) and for each trial separately. 
For the LMM analysis of heart rate variability, 5 min heart 
rates will be recorded for three times throughout the 
testing session in order to control for any change due to 
the effect of nasal spray based on different time effects. 
The primary outcome measures are the heart rates, and 
the interaction between time of recording (HB1pre vs 
HB2during vs HB3post) and nasal spray will be analysed.
We will also explore the relationship between intero-
ceptive accuracy and affective touch by means of correla-
tional analyses.37 We will also explore the extent to which 
interoceptive accuracy and affective touch can predict 
the susceptibility to the RHI by means of a hierarchical 
regression, where possible confounds would be entered 
on step one and the main variable on interest on step 2 
(as in ref 37).
In addition, analyses will be performed without the 
subjects who do not show sensitivity to CT optimal stim-
ulation for exploratory purposes (ie, negative difference 
between the pleasant of slow touch and the pleasantness of 
fast touch). This is a procedure used in previous studies,37 
which allow to check for the slow versus fast manipulation 
which is the basis of subsequent manipulation in the RHI 
paradigm. Given previous evidence showing an impair-
ment in the perception of affective touch in AN,52 this 
procedure will be applied only to the healthy participants 
group.
Finally, the same pattern of LMM analyses described 
for the subjective embodiment in the RHI will also be 
conducted with proprioceptive drift as a secondary 
outcome measure of the illusion to explore the effect of 
IN-OT on the objective mis-location of the participant’s 
hand. In addition, we will explore the effect of IN/OT 
on the affective RHI. We will run a 2×2×2 LMM analysis 
to test the effect of velocity in synchronous conditions 
only on the subjective and objective occurrence of the 
illusion (ie, affective RHI, comparison between slow and 
fast touch in synchronous conditions only) and the inter-
action between velocity of touch, group and nasal spray. 
Pleasantness ratings will also collected and analysed as 
a manipulation check that slow touch is perceived and 
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All the analyses will be conducted to investigate 
differences between groups (ie, differences between 
conditions between subjects) as well as at the group 
level (ie, differences between conditions for within 
subjects). Additionally, we will analyse the total 
embodiment score (ie, by averaging the scores of the 
different items of the embodiment questionnaires), as 
well as considering inter- and intra- individual analysis 
of variance for each of the 12 items of the embodi-
ment questionnaire separately.
DIsCussIon
This experimental study aims to mainly explore the effect 
of IN-OT as compared with placebo in AN (compared 
with healthy controls) on (1) the perceived pleasantness 
of affective, CT-optimal touch and emotionally neutral, 
non-CT optimal touch; (2) on multisensory integration 
processes underpinning the sense of body ownership in 
the classic RHI and (3) in an enhanced version where we 
manipulate the size of the hand. Furthermore, secondary, 
exploratory aims of this study include the investigation 
the effect of IN/OT on another interoceptive modality 
(namely cardiac awareness) and on the relationship 
between interoceptive accuracy, affective touch and multi-
sensory integration as measured by means of the RHI. We 
also aim to explore whether the effect of IN-OT would be 
modulated by individual differences, such as self-objectifi-
cation and eating disorders symptomatology.
In the last two decades, a growing body of research 
has explored the effect of IN-OT on human behaviour; 
nevertheless, the neural processes and the specificity of 
its effects on socio-affective functioning and bodily aware-
ness are not fully understood. IN-OT shows some prom-
ising effects on the core symptoms on AN, such as social 
cognition and as support to food therapy (eg, ref 23). 
However, there is a lack of investigation on the poten-
tial effect of IN-OT on other key features of AN, namely 
body image distortions and perception of interoceptive 
signals, such as affective touch and cardiac awareness 
(but see ref 26). To date, there is no pharmacological 
treatment which can specifically address the body image 
distortions in AN. To the best of our knowledge, this is the 
first study to systematically investigate the effect of IN/
OT versus placebo in AN at different levels of socio-af-
fective functioning and bodily-related awareness. Due 
to the multi-measures approach and the use of different 
experimental paradigms, this study can provide new 
insights in the functional mechanisms of OT on some 
of the core symptoms of AN patients. AN is the psychi-
atric disorders with the highest mortality rate.2 People 
with AN show a severe lack of awareness and often do not 
realise the severity of their condition. This unawareness 
might trigger a maintenance mechanism and discourage 
patients to engage with therapy. Hence, novel approaches 
targeting the awareness of illness (ie, both from inside 
[interoceptively] and outside [exteroceptively] the body) 
with the final aim of improving therapeutic engagement 
must be developed. A ‘healthy’ psychological experience 
of our own body is central to mental health, as revealed 
by eating and psychosomatic disorders, but also the 
somatic dimensions of other conditions such as depres-
sion and anxiety. Therefore, re-balancing the relationship 
between internal and external bodily signals can help not 
only develop treatments specific for AN patients, but also 
to prevent the development of such disorders in young 
people, targeting ages when they might be more sensitive 
to bodily as well as emotional changes.
One of the main aims of this study is to elucidate, by 
using neurobiological and behavioural methodologies, 
whether IN-OT could improve the balance between 
interoceptive and exteroceptive signals in relations to 
body representation. By targeting for the first time the 
relation between the oxytocinergic system and social, 
tactile anhedonia, interoceptive awareness and body 
representation, we aim to provide a novel but promising 
perspective on the understanding of AN. One strength 
of this study is that all the methodologies (ie, affective 
touch, cardiac awareness, RHI) have been used with AN 
patients in previous separated studies from our group 
and others49 52 71; this provides a solid base for this more 
challenging clinical and pharmacological investigation. 
In addition, the design of the present study has been 
informed by previous research investigating the effect of 
intranasal compounds on the perception of touch. For 
example, a recent study provided support to the modula-
tion of top-down expectations on the perception of touch, 
by showing that positive expectations on an inactive nasal 
spray (ie, placebo) can enhance the perceived pleasant-
ness of touch.90 This evidence highlighted the necessity to 
apply a double-blind methodology in order to avoid any 
potential influence, even if unwanted, coming from both 
the participant and/or the experimenter.
A limitation of this study is that only female subjects 
will be tested and thus findings cannot be generalised to 
males, which are increasingly being diagnosed with AN.91 
However, this limitation also increases the internal validity 
of this trial and allows for tight control of extraneous vari-
ables that might differ between male and female with 
AN. In addition, this study will investigate the effect of a 
single dose of IN-OT (40 IU); therefore, no conclusions 
about the longitudinal treatment effects can be drawn. 
Although the placebo-controlled within subject nature 
of the study offers high internal validity, it is no possible 
to conclude whether IN-OT can be used in a therapeutic 
setting as such. Hence, we hope that this study will inform 
future clinical trials to investigate the effect of multiple 
doses of IN/OT following longitudinal approaches and 
multi-point outcome measurements, and to explore the 
possibility to pair oxytocinergic therapy to other ongoing 
treatments to improve body image distortions and body 
awareness, and ultimately treatment outcome in AN.
Ethics and dissemination
Women only (16–40 years old) are selected due to differ-
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levels. Participants will be recruited from the collabora-
tion teams (LS, NELFT and PR, NoCLOR) and they will 
be provided with written information and the opportunity 
to discuss the study. The Information Sheet approved by 
the NRES committee specifies the voluntary basis of the 
patients’ participation, their right to withdraw without 
explanation or consequences and their right for a cool-
ing-off period of 7 days. No participant will be recruited 
without written, inform consent. Matched healthy 
controls will be recruited by the University College 
London subject pool.
The results will be disseminated through conference 
presentations and publication in peer-reviewed journals.
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